Latar belakang: Pemberian albumin hiperonkotik intravena lazim dilakukan pada pasien hipoalbuminemia berat (kadar albumin plasma ≤2,5 g/dl). Walaupun demikian, hingga ini, berbagai referensi menunjukkan hasil yang inkonklusif terkait manfaat "koreksi" kadar albumin pada pasien, terutama dalam menurunkan mortalitas dan morbiditas.Metode: Penelitian ini menilai karakteristik pasien hipoalbuminemia berat dan pola penggunaan albumin intravena hiperonkotik di Rumah Sakit Umum Pusat Nasional Cipto Mangunkusumo. Analisis kesintasan dilakukan dengan variabel bebas berupa pemberian albumin intravena, penyakit dasar, kadar albumin saat admisi dan sebelum pemberian, serta durasi hingga temuan hipoalbuminemia berat. Data deskriptif ditampilkan terkait pemberian albumin, yaitu mencakup jumlah yang diberikan dan respons terhadap pemberian albumin.Hasil dan Diskusi: Mayoritas pasien (79,19%) dengan kadar albumin ≤2,5 g/dl diberikan albumin hiperonkotik intravena. Insidens mortalitas 30 hari pada pasien hipoalbuminemia berat adalah 47,20%. Pemberian albumin intravena didapatkan tidak memiliki hubungan bermakna dengan kesintasan 30 hari (HR 0,902; IK 95% 0,598-1,361; p=0,624). Faktor yang berhubungan bermakna dengan kesintasan 30 pada pasien hipoalbuminemia berat adalah sepsis, syok hipovolemik, keganasan padat, serta temuan kadar albumin sebelum pemberian ≤2,0 g/dl.Kesimpulan: Pemberian albumin hiperonkotik intravena pada pasien rawat inap tidak berhubungan dengan kesintasan 30 hari.

---

Introduction: Intravenous hyperoncotic albumin administration is a common practice to be done to patients with severe hypoalbuminemia (plasma albumin level ≤2.5 g/dl). However, until now, many references has shown inconclusive results associated with "correction" of albumin level in patients, especially in reducing mortality and morbidity.

Method: This study assessed severe hypoalbuminemia patients' characteristics and pattern of use from hyperoncotic albumin intravenously in Cipto Mangunkusumo National Hospital. Survival analysis was done with independent variables including: intravenous albumin administration, underlying diseases, albumin level during admission and before albumin administration, as well as time duration from admission to severa hypoalbuminemia detection. Descriptive data was also shown associated with albumin administration consisted of amount of albumin given and response after albumin administration.

Result and Discussion: Majority of subjects (79.19%) with albumin level ≤2.5 g/dl was given hyperoncotic albumin intravenously. Incidences of 30-day mortality in severe hypoalbuminemia patients is 47.20%. There as no association between intravenous albumin administration and 30-day survival (HR 0.902; 95 CI% 0,598-1.361; p=0.624). Factors which were found associated with 30-day mortality are sepsis, hypovolemic shock, solid malignancy, and findings of albumin level ≤2.0 g/dl before albumin administration.

Conclusion: Hyperoncotic intravenous albumin administration didn't associate with 30-days survival.